Phase I/II clinical trial of a helper peptide vaccine plus PD-1 blockade in PD-1 antibody-naïve and PD-1 antibody-experienced patients with melanoma (MEL64)

BACKGROUND: A vaccine containing 6 melanoma-associated peptides to stimulate helper T cells (6MHP) is safe, immunogenic, and clinically active. A phase I/II trial was designed to evaluate safety and immunogenicity of 6MHP vaccines plus programmed death 1 (PD-1) blockade. PARTICIPANTS AND METHODS: Pa...

Descripción completa

Detalles Bibliográficos
Autores principales: Vavolizza, Rick D, Petroni, Gina R, Mauldin, Ileana S, Chianese-Bullock, Kimberly A, Olson, Walter C, Smith, Kelly T, Dengel, Lynn T, Haden, Kathleen, Grosh, William W, Kaur, Varinder, Varhegyi, Nikole, Gaughan, Elizabeth M, Slingluff, Craig L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472210/
https://www.ncbi.nlm.nih.gov/pubmed/36100309
http://dx.doi.org/10.1136/jitc-2022-005424

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9472210/
https://www.ncbi.nlm.nih.gov/pubmed/36100309
http://dx.doi.org/10.1136/jitc-2022-005424

Ejemplares similares